-
Exagamglogene autotemcel, sold
under the
brand name Casgevy, is a gene
therapy used for the
treatment of
sickle cell
disease and transfusion-dependent...
-
Lovotibeglogene autotemcel, sold
under the
brand name Lyfgenia, is a
lentiviral gene
therapy used for the
treatment of
sickle cell disease. The most common...
-
Atidarsagene autotemcel, sold
under the
brand name
Libmeldy among others, is a gene
therapy treatment for
metachromatic leukodystrophy developed by Orchard...
-
Elivaldogene autotemcel, sold
under the
brand name Skysona, is a gene
therapy used to
treat cerebral adrenoleukodystrophy (CALD). It was
developed by Bluebird...
-
Betibeglogene autotemcel, sold
under the
brand name Zynteglo, is a gene
therapy for the
treatment for beta thal****emia. It was
developed by
Bluebird Bio...
- the
United States for its one-time
treatment Zynteglo (betibeglogene
autotemcel). Gene
editing therapies aimed at
increasing fetal hemoglobin production...
-
Award (FOYA)
award in 2022. The company’s lead program,
exagamglogene autotemcel, or exa-cel (formerly CTX001), was
granted regulatory approval by the...
-
neurological symptoms,
plasma VLCFA levels remained elevated.
Elivaldogene autotemcel is
pending authorization by the
European Commission as of May 2021[update]...
- company's only - in the
European Union (EU) -
approved drug is
betibeglogene autotemcel (Zynteglo),
which treats transfusion-dependent beta thal****emia (TDT)...
-
lymphoma Beremagene geperpavec (Vyjuvek):
treatment of wounds.
Betibeglogene autotemcel (Zynteglo):
treatment for beta thal****emia
Brexucabtagene autoleucel (Tecartus):...
